Dr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and pla...

The healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...

Glenmark anticipates innovative products will drive nearly seventy percent of its revenue. This strategic shift moves the company away from...

India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disea...

South Africa's regulator approved Sun Pharma's generic semaglutide injection for diabetes. This approval allows marketing to supplement die...

Markets saw a strong rebound on Friday, driven by global cues and IT earnings. HCL Tech and ICICI Pru AMC will announce their first quarter...

Dr Reddy's Laboratories will halt semaglutide injection supplies until at least October. Unspecified impurities were identified during the ...

Indian pharmaceutical firms anticipate revenue increases in the first quarter of fiscal year twenty twenty six twenty seven. Profitability ...

Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue ...

Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batche...

Novo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth,...

Despite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges wi...

Initial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

The landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...

Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...